Epstein-barr virus in inflammatory bowel disease-correlation with different therapeutic regimens

Inflammatory Bowel Diseases

Volumn 19, Issue 8, 2013, Pages 1710-1716

  Magro, Fernando ^a,b,c   Santos Antunes, João ^a,d   Albuquerque, Andreia ^a   Vilas Boas, Filipe ^a   Macedo, Gonçalo N ^e   Nazareth, Nair ^e   Lopes, Susana ^a   Sobrinho Simões, Joana ^a   Teixeira, Sérgio ^a   Dias, Cláudia Camila ^d   Cabral, José ^b   Sarmento, Amélia ^c,e   Macedo, Guilherme ^a  

^a Centro Hospitalar Universitário de São João   (Portugal)

^b University of Porto   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

^d UNIVERSITY OF PORTO   (Portugal)

^e UNIVERSIDADE FERNANDO PESSOA   (Portugal)

Author keywords

Azathioprine; Epstein barr virus; Inflammatory bowel disease; Infliximab

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; INFLIXIMAB; MESALAZINE; VIRUS DNA;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROHN DISEASE; DNA DETERMINATION; DRUG UTILIZATION; ENTERITIS; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; ULCERATIVE COLITIS; VIRUS LOAD;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; CASE-CONTROL STUDIES; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MALE; MESALAMINE; MIDDLE AGED; PORTUGAL; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84884550522     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e318281f31c     Document Type: Article

References (15)

1. Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929-936.
2. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374: 1617-1625.
3. Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54:1121-1125.
4. Dayharsh GA, Loftus EV Jr, Sandborn WJ, et al. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology. 2002;122:72-77.
5. Lavagna A, Bergallo M, Daperno M, et al. Infliximab and the risk of latent viruses reactivation in active Crohn's disease. Inflamm Bowel Dis. 2007; 13:896-902.
6. Sokol H, Beaugerie L. Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle. Gut. 2009;58: 1427-1436.
7. Rickinson A. Epstein-Barr virus. Virus Res. 2002;82:109-113.
8. Saha A, Robertson ES. Epstein-Barr virus-associated B-cell lymphomas: pathogenesis and clinical outcomes. Clin Cancer Res. 2011;17: 3056-3063.
9. Reijasse D, Le Pendeven C, Cosnes J, et al. Epstein-Barr virus viral load in Crohn's disease: effect of immunosuppressive therapy. Inflamm Bowel Dis. 2004;10:85-90.
10. Lewis JD, Bilker WB, Brensinger C, et al. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology. 2001;121: 1080-1087.
11. Askling J, Brandt L, Lapidus A, et al. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut. 2005;54: 617-622.
12. Baecklund E, Ekbom A, Sparen P, et al. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ. 1998;317:180-181.
13. Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54:692-701.
14. Gulley ML, Tang W. Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder. Clin Microbiol Rev. 2010;23:350-366.
15. Stevens SJ, Verschuuren EA, Pronk I, et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in highrisk patients. Blood. 2001;97:1165-1171.